NCT00882570

CompletedPhase 1

To Demonstrate the Relative Bioequivalence of Cefdinir and O...

Sandoz Source

ClinicalTrials.gov

Compare

Other study identifiers

Sponsor study identifier

50040

Study Type

interventional

Actual enrollment (reported)

40

Locations

0 countries

Sites

N/A

Timeline

Study Start

April 2005

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

May 2005

Actual (reported)

Study Completion

May 2005

Actual (reported)

Brief Summary

To demonstrate the relative bioequivalence of Cefdinir and Omnicel 250mg/5 ml fasting conditions.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 40 participants
Study completion date: May 2005
Actual (reported)
Listed locations: 0 countries · 0 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
April 2005
Date type not reported
This date has not been verified as actual or estimated.
Primary Completion
May 2005
Actual (reported)
Study Completion
May 2005
Actual (reported)
First Submitted
April 15, 2009
Actual (reported)
First Posted
April 16, 2009
Actual (reported)

Last Updated: March 29, 2017
Status Verified: April 2009
Last Update Submitted: March 27, 2017

Conditions

Healthy

Keywords

Antibiotic

Outcome Measures

Primary Outcomes (1)

Bioequivalence based on AUC and Cmax
10 days

Study Arms (2)

1

EXPERIMENTAL

Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria)

Drug: Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria)

2

ACTIVE COMPARATOR

Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)

Drug: Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)

Interventions

Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria)Drug

1

Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)Drug

2

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 56 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64)

You may qualify if:

No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

You may not qualify if:

Sponsors & Collaborators

Sandoz
Industrylead

MeSH Terms

Interventions

CefdinirSuspensions

Intervention Hierarchy (Ancestors)

Cephalosporinsbeta-LactamsLactamsAmidesOrganic ChemicalsThiazinesSulfur CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsColloidsComplex MixturesDosage Forms

Study Officials

Richard Larouche, M.D.
SFBC Anapharm
PRINCIPAL INVESTIGATOR

Enrollment

40 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 1
Allocation: RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: CROSSOVER
Sponsor Type: INDUSTRY

Study Record Dates

First Submitted

April 15, 2009

First Posted

April 16, 2009

Study Start

April 2005

Date type not reported

This date has not been verified as actual or estimated.

NCT00881400

To Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Fed Conditions

Phase 1Completed

NCT00881426

To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fasting Conditions

Phase 1Completed

NCT00881855

To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fed Conditions

Phase 1Completed

NCT00881179

To Demonstrate the Relative Bioavailability of Clarithromycin 250 mg Tablets Under Non-Fasting Conditions

Phase 1Completed

NCT00881738

To Demonstrate the Relative Bioavailability of Clarithromycin 250 mg Tablets Under Fasting Conditions

Phase 1Completed

NCT00835549

Cefdinir for Oral Suspension 250 mg/5mL, Non-fasting

Phase 1Completed

Positive test results for HIV or hepatitis B or C.

Treatment for drug or alcohol dependence.

Contact the study team to confirm eligibility.

Pharmaceutical Preparations

Primary Completion

May 2005

Actual (reported)

Study Completion

May 2005

Actual (reported)

Last Updated

March 29, 2017

Record last verified: 2009-04

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00882570
Data provider: ClinicalTrials.gov
Source updated: 2017-03-29
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:27:49 UTC

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

1

2

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record